Haemonetics Corp (NYSE:HAE)
$ 95.27 -0.46 (-0.48%) Market Cap: 4.84 Bil Enterprise Value: 5.49 Bil PE Ratio: 41.60 PB Ratio: 5.04 GF Score: 84/100

Haemonetics Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 12:45PM GMT
Release Date Price: $65.66 (+3.70%)
Andrew Christopher Ranieri
Morgan Stanley, Research Division - Equity Analyst

Welcome, everyone, to day 1 of the Morgan Stanley Healthcare Conference. I'm Drew Ranieri, one of the medical device analysts here. It's my pleasure to have Chris Simon, President and Chief Executive Officer of Haemonetics with us here today. And there's a significant amount to talk about.

But before we jump into it, just a quick disclaimer. But for important disclosures, please see the Morgan Stanley research disclosure website at morganstaley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep.

But Chris, thanks for being here today. I really appreciate it for -- and thank you for your time.

Questions & Answers

Andrew Christopher Ranieri
Morgan Stanley, Research Division - Equity Analyst

And I just want to start off this morning maybe on the Plasma business and kind of where recovery stands. So recovery in plasma collection continues to be kind of -- continues to lag, especially in your first quarter.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot